scispace - formally typeset
T

Tae Hyung Kim

Researcher at Korea University

Publications -  70
Citations -  559

Tae Hyung Kim is an academic researcher from Korea University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 9, co-authored 46 publications receiving 366 citations. Previous affiliations of Tae Hyung Kim include Korea University Medical Center.

Papers
More filters
Journal ArticleDOI

Clinical usefulness of psoas muscle thickness for the diagnosis of sarcopenia in patients with liver cirrhosis.

TL;DR: In this article, the optimal cutoff values of psoas muscle thickness per height (PMTH) for detecting sarcopenia in patients with cirrhosis were evaluated and the best PMTH cutoff values for predicting SMI-sarcopenia were 17.3 mm/m in men and 10.4 mm/mm in women.
Journal ArticleDOI

Tumor carbonic anhydrase 9 expression is associated with the presence of lymph node metastases in uterine cervical cancer.

TL;DR: Findings indicate that expression of CA9, but not CA12, in tumors is associated with the presence of LN metastases and poorer prognosis, and selective application of new treatment modalities based on CA9 expression to prevent Ln metastases may improve overall treatment outcome in patients with uterine cervical cancer.
Journal ArticleDOI

BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A.

TL;DR: The prognosis of patients with SLHCC is investigated to determine the most appropriate BCLC stage designation for single large HCC (SLHCC, single nodule > 5 cm).
Journal ArticleDOI

Remodelling of nasal mucosa in mild and severe persistent allergic rhinitis with special reference to the distribution of collagen, proteoglycans, and lymphatic vessels.

TL;DR: Small leucine‐rich repeat proteoglycans (decorin, biglycan, and lumican), collagen, and lymphangiogenesis are involved in tissue remodelling of various organs with inflammatory diseases.
Journal ArticleDOI

Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis.

TL;DR: Suppression of hepatitis B virus DNA is more potent, and occurrence of resistant strain is rare with entecavir than lamivudine, but whether these merits result in a more favourable outcome in HBV‐related decompensated cirrhosis patients is unclear.